Novo Nordisk's Two-Front Week: Paediatric Progress on Wegovy, But a Cardiology Programme Unravels
Published on 09/08/2026 at 14:02 | Editorial boerse-global.de
Monday delivered a study in contrasts for Novo Nordisk investors. The Danish drugmaker posted encouraging Phase 3 results for its blockbuster obesity therapy in young children, yet simultaneously pulled the plug on two late-stage trials for its heart-failure candidate Ziltivekimab. The juxtaposition captures the central tension weighing on the stock: a company whose scientific engine keeps delivering in weight loss, but whose efforts to diversify beyond that franchise keep stalling.
A First-in-Class Win in the Under-12 Set
The STEP Young study met its primary endpoint, marking the first successful trial of its kind in children aged six to under twelve with obesity. After 68 weeks on semaglutide at doses of 1.7 and 2.4 milligrams, more than 40 percent of treated children no longer met the obesity threshold, compared with zero percent in the placebo arm. Notably, over 85 percent of participants entered the trial with severe Class II or III obesity. The safety profile showed no new concerns.
Novo Nordisk plans to present the full dataset at the ObesityWeek congress in Washington this November. A regulatory filing for this age group remains a future step, but the data lay the scientific groundwork. The strategic logic is clear: establishing an early foothold in a paediatric population that has historically received little pharmacological attention — and one where rival Eli Lilly has yet to field comparable evidence.
That said, the commercial timeline warrants caution. Paediatric approvals move slowly, and the revenue contribution from this indication is unlikely to move the needle in the near term.
The Cardiology Setback That Complicates the Narrative
The same day, Novo Nordisk terminated the HERMES and ATHENA Phase 3 trials of Ziltivekimab, an IL-6 inhibitor being developed for heart failure, after a committee judged the probability of positive outcomes too low. This marks the second failure for the programme within weeks, following the collapse of the ZEUS study in July. Only the ARTEMIS trial in post-heart-attack patients continues, with results expected in the first half of 2027.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The setback carries a sting beyond the clinical disappointment. Ziltivekimab originated from the 2020 acquisition of Corvidia, a deal worth 725 million US dollars. Two failed studies in quick succession raise uncomfortable questions about capital allocation, even if the programme never formed the core of the investment thesis.
Context helps, however. Novartis simultaneously disclosed that its cardiovascular candidate Pelacarsen missed its primary endpoint in an advanced trial. The pattern suggests the broader difficulty of developing new heart drugs — a sector-wide challenge rather than a Novo Nordisk-specific failing.
What the Price Action Says
The shares traded around 39.60 to 39.83 euros on Monday, roughly 27 to 28 percent below the 52-week high of 54.86 euros reached in January. The stock remains about 31 percent above its March trough of 30.25 euros, reflecting a meaningful recovery from the lows without a return to previous peaks. The Relative Strength Index of 46.8 points to a market that has absorbed the mixed headlines without panic — neither oversold nor overbought.
Analyst sentiment remains guarded. Barclays' James Gordon trimmed his price target from 310 to 300 Danish kroner, holding an "Equal Weight" rating. The adjustment stems from currency-related estimate changes rather than operational deterioration, yet it underscores that positive clinical news alone is not shifting Wall Street's cautious stance. Deutsche Bank had already moved to "Sell" in late August, a position the Ziltivekimab news seems unlikely to soften.
Demand Signals Bear Watching
Beyond clinical headlines, early signs of demand softening are emerging. Brazilian import data for polypeptide hormone-based medications — a proxy for weight-loss injection demand — fell 22 percent in August compared with July, according to Citi. The figure is regional and preliminary, but it hints at the pricing pressure and competitive dynamics, including generics and biosimilars, that are becoming harder to ignore.
The Road Ahead
All eyes now turn to London, where incoming chief executive Mike Doustdar is expected to deliver a major strategy address in roughly two weeks. For market watchers, that speech may prove more consequential than any single trial readout, offering clarity on how Novo Nordisk intends to prioritise investment across diabetes, obesity, and the broader pipeline.
The November ObesityWeek presentation will provide a fuller picture of the paediatric data. Whether that proves sufficient to win over sceptics remains an open question. For now, investors are weighing a company that continues to demonstrate scientific leadership in its core franchise while struggling to prove it can replicate that success elsewhere — and facing the first hints that even Wegovy's growth may not be limitless.
Ad
Novo Nordisk Stock: New Analysis - 8 September
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
